Solange Peters

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

Solange Peters, Byoung Chul Cho, Alexander Luft et al. · Journal of Thoracic Oncology · 2024 · 47 citations · Full text

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Luis Paz‐Ares, Hossein Borghaei, Stephen V. Liu et al. · The Lancet · 2025 · 38 citations

First-line Maintenance Therapy, Medicine, Pathology +6

Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC

Solange Peters, Roy S. Herbst, Hidehito Horinouchi et al. · Cancer Research · 2025 · 16 citations

Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

Cesare Gridelli, Solange Peters, Tony Mok et al. · Lung Cancer · 2023 · 14 citations · Full text

First Line Treatment, Oncology, Italian Association +9